These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22085508)

  • 1. [The multidisciplinary practice guideline "The responsible use of biologicals"].
    Bijlsma JW; Hagemeijer JW; Bijl M; Jansen TL; van de Laar MA; Landewé RB; Nurmohamed MT
    Ned Tijdschr Geneeskd; 2011; 155(30-31):A3114. PubMed ID: 22085508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Introduction to biological drugs].
    Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital.
    Chan G; Goh F; Hodgson T; Hsu E; Johnstone D; Ly J; Platt T; Rodrigues E; Tsai W; Hider P; Gray A; Highton J
    N Z Med J; 2008 May; 121(1274):34-41. PubMed ID: 18535644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 5. Infections during treatment with biological agents and possible treatment in clinical practice.
    Atzeni F; Benucci M; Sarzi-Puttini P
    Expert Rev Clin Immunol; 2013 Mar; 9(3):193-5. PubMed ID: 23445193
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriatic arthritis treatment: biological response modifiers.
    Mease PJ; Antoni CE
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii78-82. PubMed ID: 15708944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
    [No Abstract]   [Full Text] [Related]  

  • 12. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic arthritis - treatment update.
    Mease PJ
    Bull NYU Hosp Jt Dis; 2011; 69(3):243-9. PubMed ID: 22035437
    [No Abstract]   [Full Text] [Related]  

  • 15. [Statement of the German Society of Rheumatology (DGRh) reporting on the Institute's plan for biologicals in the second-line therapy for rheumatoid arthritis].
    Braun J; Krüger K; Genth E
    Z Rheumatol; 2011 Dec; 70(10):882-3. PubMed ID: 22139207
    [No Abstract]   [Full Text] [Related]  

  • 16. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile idiopathic arthritis - an update on pharmacotherapy.
    Kahn P
    Bull NYU Hosp Jt Dis; 2011; 69(3):264-76. PubMed ID: 22035441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
    Beresford MW; Baildam EM
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
    Mushtaq S; Goodman SM; Scanzello CR
    Am J Ther; 2011 Sep; 18(5):426-34. PubMed ID: 20216205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.